Rockville, MD—U.S. retail sales of cannabis and
cannabidiol (CBD) products reached $14 billion in 2019, and are on pace
to increase 18% per year to $33 billion in 2024, according to data
published in a new report from Packaged Facts titled Cannabis and CBD: U.S. Retail Market Trends and Opportunities.
The most common delivery format for cannabis, the flower—smoked as
buds or as cigarettes—accounts for nearly 40% of retail sales, according
to a press release. Vaporizer cartridges with concentrated THC or CBD
compounds takes the second largest share, but it’s falling, as concerns
about vaping-related lung illnesses rise. Edibles and topicals are
predicted to rise, and to rise quickly, as they stand to benefit the
most from legalization of hemp-based CBD; major retailers are already
offering CBD-infused food and beverages, as well as CBD-infused
cosmetics.
The report analyzes cannabis and cannabis-related retail trends and
opportunities in the U.S., with a focus on multi-state cannabis
dispensary operators and food and beverage introductions, as well as
market trends by state. It also includes a detailed analysis of
cannabis-related legal and regulatory trends at the federal and state
levels. The report can be purchased here.
BREAKING: Signed $20,000,000 Letter of Intent To Acquire Venom Extracts (“Venomâ€)
HIGHLY ACCRETIVE $20,000,000 ACQUISITION
Venom Highlights
2019 Est Revenue ~C$16.4M; EBITDA ~C$2.48M
30% Of Acquisition Price Paid If Venom Revenues Hit $30,000,000 and $40,000,000 By DEC 31, 2021
Average revenue per gram YTD 2019 $CDN 14 and will continue to increase as vape cartridge mix grows ($CDN 30 per gram)
One Of Arizona’s Largest Producers Of Award-Winning Medical Cannabis Distillate
Acquisition Expected To Close By March 31, 2020 Subject To Due Dilligence
An established brand in Arizona for high quality
products in the wholesale and distillate marketplace. Venom is
leveraging its brand and success to aggressively expand into other US
states.
ACQUISITION TERMS
Hollister will acquire Venom Extracts for CDN$20,000,000 via Hollister stock
The stock price will be determined based on the greater of:
The 14-day VWAP (Volume Weighted Average Price) capped at $0.25 subsequent to announcing the transaction and $0.20
Once share price is established, 70% of the Payment Shares will be issued upon closing of the transaction
Remaining
30% of the Payment Shares will be issued when and if the following
milestones have been met on or prior to December 31st, 2021
Hollister Highlights Of Current Operations:
Hollister’s products are now present in 220 of 600 California dispensaries.
Vision is to capitalize on this success to become the sought after
premium brand portfolio of Cannabis across multiple states and Hemp
nationwide
Major LOI, Joint Ventures and Licensing Agreements Support Proof Of This Vision
“Easy Riders” – Milliions Of Global Followers
“Tactical Relief” – Veteran Founded, Hemp Based CBD Brand With Nation Wide Members
“Tommy Chong” – Exclusive Manufacture & Distribution Of Tommy Chong’s Cannabis (TM) Full Spectrum Elixir 1:1
“I only partner with the best-in-class companies and I am really
pleased to have the Hollister Cannabis Co. bring their amazing Tommy
Chong’s Cannabis™ Full Spectrum Elixir to the market for me”.
– Tommy Chong
KEY JOINT VENTURES AND PARTNERSHIPS DETAILS
LOI for a proposed offtake agreement with Mountain Financial Solutions LLC
Hollister will purchase 1,000 pounds of hemp from Mountain Financial
(unique high CBD hemp strains ) for use in various smokable hemp
products – specifically, Rebel Hemp Company’s premium hemp pre-rolls.
Licensing agreement with Tommy Chong to manufacture and distribute Tommy Chong’s Cannabis™
Full Spectrum Elixir 1:1.
The tincture, features a 1:1 ratio of THC to CBD, recognized for its medicinal properties
Distributed exclusively by Indus and is anticipated to be in-dispensaries throughout California by March 01, 2020.
Anticipating producing up to 25,000 units of during the 1st 12 months with an estimated retail price of $70 per unit
LOI with ER71 USA Inc. (“Easyriders”) an iconic brand with millions of followers globally, have entered into LOI to complete a joint venture agreement
Upon completion of the Joint Venture, Hollister and Easyriders will
collaborate on the development and marketing of co-branded hemp based
everyday premium product lines.
Pre-rolled products using hemp
JV will further explore the development and marketing of additional product SKU’s for hemp-based
Edibles
Vapes
Topicals
beverages.
Revenue generated on the co-branded product lines will be shared 50:50 between Easyriders and Hollister.
Hollister Biosciences Inc. and Veteran Based Tactical Relief Enter into Letter of Intent for Proposed Joint Venture Agreement
Upon completion of the Agreement, Hollister and Tactical Relief will collaborate on the development and marketing of cannabis tinctures throughout the California market
Branded under Tactical Relief, the first cannabis tincture to be
manufactured will feature a 20:1 ratio of THC to CBD, recognized for its
medicinal properties in treating PTSD
Will be distributed exclusively by Hollister’s distribution partner, Indus Holdings Inc.
Hollister Currently Manufactures The Following Products:
hash
hash infused products
tinctures
crumble infused products
Pre-rolls
Vape Products
Pet CBD
Cannabis Concentrate
Brewed Hemp Beverages
Premium Hemp Pre-Rolls
other cannabis products
HashBones
Hashbones are a pre-roll made from 75% cannabis flower blended in small batches with 25% bubble hash
Results in a more potent pre-roll, also maintains the integrity of the cannabis
Terpenes are preserved in the bubble hash production process
Bubble hash is made without solvents or chemicals and is one of the cleanest concentrates available on the market
Hollister’s trusted and highly rated brand of pre-rolls, sold via third-party retailers
Mighty Meds
Acquired Mighty Meds as its vape brand
Company’s vape products are manufactured from pure THC distillate
and plant-based terpenes and do not use any additives that have been
linked to health issues.
San Diego based
Produces discreet, disposable, health conscious vape cartridges and other products
Purity Petibles
Purity Petibles 20:1 CBD pet tincture is manufactured using full
spectrum CBD, organic MCT Oil derived from coconuts and chicken flavor
The MCT Oil and chicken flavor used in Purity Petibles is food grade
Rebel Tea
Brewed with high-quality, American-grown
hemp and containing fifteen milligrams of whole-plant full-spectrum
phytocannabinoids, Rebel Tea offers consumers a refreshing THC-free
beverage. Rebel Tea’s innovative formula features exclusively organic
ingredients paired with light flavoring from natural lemon and cane
sugar.
NanoPure
NanoPure, nano-emulsified cannabis concentrate which will be sold both:
Wholesale as an ingredient for other companies and
power products for Hollister Cannabis Co.
DISTRIBUTION
Hollister has an exclusive distribution agreement in place with Indus Holdings (CSE: INDS).
Indus is the licensed California distributor that operates the WAYV platform.
Indus currently manages all of Hollister’s product fulfilment
obligations, allowing Hollister to focus its efforts on production and
marketing.
Indus provides Hollister with full brand representation by utilizing
its 15 sales reps to represent Hollister’s product to the California
marketplace.
Through Indus, Hollister’s products are now present in 220 dispensaries throughout California.
US CANNABIS MARKET STATS
CALIFORNIA CANNABIS MARKET STATS
HEMP
The Company intends to move into the hemp market. While cannabis is
still restricted by state regulations, CBD is not. We plan on leveraging
the brand by distributing hemp and CBD versions of our products
nationwide. We will strive to have the Rebel Hemp Co brand touch every
corner of the country.
CORPORATE STRUCTURE
Hollister develops quality branded cannabinoid-based and hemp-based
consumer goods and products for large-scale distribution through two
companies: Hollister Cannabis Co. and Rebel Hemp Company.
Posted by AGORACOM-JC
at 5:20 PM on Tuesday, February 25th, 2020
SPONSOR: CardioComm Solutions (EKG: TSX-V)
– The heartbeat of cardiovascular medicine and telemedicine. Patented
systems enable medical professionals, patients, and other healthcare
professionals, clinics, hospitals and call centres to access and manage
patient information in a secure and reliable environment.
Apple, J&J Launch New mHealth Study Targeting Wearables and AFib
Apple is partnering with Johnson & Johnson on a new mHealth study to determine whether the Apple Watch and an accompanying app can help reduce the risk of stroke in older Americans.
The Heartline Study is open to the more than 40 million seniors enrolled in Medicare
Goal is to determine whether the ECG sensor and app on the Apple Watch can accurately detect the presence of atrial fibrillation, a key indicator of stroke susceptibility.
The Heartline Study
is open to the more than 40 million seniors enrolled in Medicare. Its
goal is to determine whether the ECG sensor and app on the Apple Watch
can accurately detect the presence of atrial fibrillation, a key
indicator of stroke susceptibility.
“Right now, we rely on symptoms – such as quivering, fluttering or
irregular heart rhythm – to detect AFib,†Michael Gibson, MD, CEO of the
Baim Institute for Clinical Research, founder of the Perfuse Study
Group at Harvard Medical School and a co-leader on the study, said in a story on the J&J website.
“But the hope is that a wearable device could detect an irregular heart
rhythm earlier, since people may not be able to recognize symptoms
without assistance. It could act like a warning light that allows a
mechanic to detect whether something’s wrong before the car actually
breaks down.â€
Gibson will head the study alongside John Spertus, MD, the Daniel J.
Lauer/Missouri Endowed Chair in Metabolic and Vascular Disease Research
at the University of Missouri at Kansas City.
This study follows on the heels of the Apple Heart Study,
to date the largest analysis of mHealth data from a wearable device.
Launched in 2017 by the Stanford University School of Medicine, Apple
and American Well, the study attracted almost 420,000 participants and
laid the groundwork for the viability of ECG sensors for detecting AFib.
“The study’s findings will help patients and clinicians understand
how devices like Apple Watch can play a role in identifying atrial
fibrillation, a deadly and often undiagnosed disease,†Mintu Turakhia,
MD, an associate professor of cardiovascular medicine at Stanford, said
when the study’s results were released in 2019. “Additionally, these
important findings lay the foundation for further research into the use
of emerging wearable technologies in clinical practice and demonstrate
the unique potential of large-scale app-based studies.â€
But that study raised concerns because it wasn’t focused on one
particular population, leading to worries that such digital health tools
could cause more harm than good.
This time around, investigators are homing in on a population facing a significant risk of stroke.
“Each year more than 795,000 people have a stroke in the US, and
some studies have shown that many people would rather die than live with
the aftereffects of a disabling stroke,†Gibson said. “Secondly, we
have an aging population, so there are more and more older patients
around the world. These are exactly the patients who are at the highest
risk of atrial fibrillation, which is associated with a significant
increase in the risk of stroke. But the good news is that these strokes
may be preventable.â€
‘By having the study focus on the highest risk patients, my hope is
that we can potentially help participants improve their heart health,â€
he added.
Participants in the study will use an Apple Watch and Heartline Study
app, which alerts the user when the smartwatch detects an irregular
heart rhythm and advises him or her to seek advice from a healthcare
provider. The app, which also provides information and resources to the
user, can be triggered to personalize that information if a care
provider confirms an AFib diagnosis or if the user isn’t engaged with
the program.
“The decision to take action is the responsibility of the
participant, but the Heartline Study app will provide additional
prompting and educational materials to help people make informed
decisions,†Gibson said.
“I’m excited about this part of the study because, as physicians,
we need to get a better handle on how often that lack of action
happens,†he added. “While it’s clear that patients often don’t take the
medicines they’re prescribed – and, in fact, often don’t even pick them
up from the pharmacy – this study could provide more solid data and
help us learn more about how often patients don’t respond to warnings
about abnormalities in their health.â€
In time, he said, researchers hope to understand more about why
people might not take part in this type of study and develop patient
engagement techniques that promote participation and reduce barriers to
care.
Tags: EKG, mhealth, small cap stocks, stocks, tsx Posted in CardioComm Solutions | Comments Off on #Apple, #J&J Launch New #Mhealth Study Targeting #Wearables and #AFib SPONSOR: CardioComm Solutions $EKG.ca – $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca
Posted by AGORACOM-JC
at 4:56 PM on Tuesday, February 25th, 2020
SPONSOR: BetterU Education Corp.
aims to provide access to quality education from around the world. The
company plans to bridge the prevailing gap in the education and job
industry and enhance the lives of its prospective learners by developing
an integrated ecosystem. Click here for more information.
4 Reasons Why The EdTech Industry Is Set To Take Off
Education Sector is Ripe for Disruption
Increasing User Base of Mobile Phones and Internet
With the influx of smart devices, Internet and advanced software, the
scope of education is expanding to every nook and corner of India. The
impact of edtech
on not just the education sector but broadly on the society is
applaud-worthy, which is why the edtech sector is also highly popular
among aspiring start-ups.
Online learning and courses are growing at a rapid pace as
professionals realize the lack of skill-based courses and poor
infrastructure in the Indian education system is now affecting their
careers.
In the last few years, an increasing number of entrepreneurs have
also realized the potential of edtech. The uptrend will continue, thanks
to the Digital India campaign, the cultural importance of education in Indian society, and low mobile data prices.
Private equity and venture capitalfirms are also keenly
investing in this sector and not just in K–12 (kindergarten to 12th
grade) but also in online courses. Supplemental courses, test
preparation, online certification and gamification have vast potential
that is yet to be explored.
Education Sector is Ripe for Disruption
The Indian education system has been following the same traditional
approach for decades. Even though the Indian culture has always laid
high emphasis on education, yet it has seen a minimal transformation. To
reform the country into a digitally empowered nation, the Indian
government has also launched the initiative Digital India.
The education sector is ripe for disruption—ranging from government
initiatives to steps taken by educational institutions. The country is
seeing a massive wave of revolution in the edtech sector. Schools and
universities are embracing digital educational tools, and even offices
are encouraging their employees to take up online courses to be more
efficient and productive.
Increasing User Base of Mobile Phones and Internet
The penetration of smartphones and cheap data rates
has been a game-changer for the edtechs. Today, there are over 350
million mobile phone users in India, which is expected to double by
2022. With these numbers, there is no doubt that mobile phones and
digital devices are the classrooms of the future.
Online courses, virtual classrooms, digital teaching tools in
classes, and through the increasing use of cutting-edge technologies
such as virtual reality, artificial intelligence and augmented reality,
the delivery and methodology of learning is changing. Not just the
learners and educators, but entrepreneurs are becoming increasingly
aware of the potential of technology in education.
The Young Are Leading the Way
The workplaces have changed drastically, and the education system
must change along. The edtech sector is helping fill the gaps between
the education system and the professional world—it is aiding individuals
to develop practical skills in addition to the theory taught in
classrooms.
Edtech entrepreneurs, or edupreneurs,
are mostly young minds who are passionate about technology and
aspirational. They are revolutionizing the education sector by launching
unique initiatives and balancing technology with learning, helping it
reach students, teachers and parents across metros, and tier II and III
cities.
Personalization of Education
With technology, the educators (teachers, professors, and educational
institutions) will be able to strategize and customize the syllabi as
per each student. The various educational programmes today are
addressing the distinct interests, learning requirements and aspirations
of a learner structure.
Online courses are offering the masses a flexible and affordable way
to acquire new skills. The advancements in education are helping people
access education easily, rise above traditional bookish knowledge, and
gain a better understanding of a subject through videos, online study
material and educational apps with a variety of learning tools.
Education in India is yet to go a long way, but the edtech sector is overcoming the hurdles one at a time.
Posted by AGORACOM-JC
at 4:00 PM on Tuesday, February 25th, 2020
At a time when Cannabis stocks are struggling and in a massive state of flux, due to an inability to actually deliver real businesses, Hollister Biosciences (HOLL:CSE) has been quietly building a real business, products, revenue and customers in 220 of California’s 600 dispensaries …. and growing, including California’s #1 hash infused pre-roll “Hashbone”.
In addition to that, Hollister has also signed LOI’s, JV’s and licensing deals with major partners with massive nationwide and even global audiences launching in the next couple of months. We’ll save details of those for another day but suffice it to say one of those partners is the world renowned Tommy Chong (of Cheech & Chong) who stated:
“I only partner with the best-in-class companies and I am really pleased to have the Hollister Cannabis Co. bring their amazing Tommy Chong’s Cannabis™ Full Spectrum Elixir to the market for me”.
If that was all Hollister had going, they’d be in great shape with a super bright future and better than most Cannabis companies (small and large) who can’t even get product out the door.
BUT THERE’S MORE – THE $20,000,000 ACQUISITION THAT COMES WITH $CDN 16.4M REVENUE & $CDN 2.48M EBITDA
Earlier today, Hollister announced an LOI to acquire Venom Extracts, one of Arizona’s largest producers of Award-Winning Medical Cannabis Distillate. Just how good is Venom? In 2019, Venom generated $CDN 16.4M in revenue and $CDN 2.48M EBITDA in 2019 (subject to due diligence confirmation) … and all of that was just from the state of Arizona! Venom CEO Mason Cave and his team have aggressive plans to expand its brand and success into other states, including California as it benefits from Hollister’s distribution into 220 dispensaries. Â
If you think “growth talk is cheap” (which is often the case), consider the fact that 30% of Venom’s $20,000,000 sale price kicks in if/when revenues hit $CDN 30,000 and $CDN 40,000 …. by December 31, 2021. In my experience, companies joining forces don’t include such terms if there isn’t a reasonable expectation for hitting those numbers. It doesn’t guarantee it but you can bet they have good reason to believe Venom sales will get to one or both of those numbers in just 21 months from now.
If you’re looking for Cannabis companies that are going to survive and thrive over this next decade, then grab your favourite beverage and watch this interview with Hollinger President, Alex Somjen.
We loved what we heard and look forward to your feedback in Hollister’s CEO Verified Forum below!
Posted by AGORACOM
at 2:00 PM on Tuesday, February 25th, 2020
Sponsor: Loncor is a Canadian gold explorer that controls over 2,400,000 high grade ounces outside of a Barrick JV. The Ngayu JV property is 200km southwest of the Kibali gold mine, operated by Barrick, which produced 800,000 ounces of gold in 2018. Barrick manages and funds exploration at the Ngayu project until the completion of a pre-feasibility study on any gold discovery meeting the investment criteria of Barrick. Newmont $NGT$NEM owns 7.8%, Resolute $RSG owns 27% Click Here for More Info
There is a dense yellow metal that is currently in the midst
of a global bull market amid the least amount of fanfare that I can
recall. The metal is gold and the bull market is very real and gaining
momentum by the day.
Gold is breaking out to all-time highs in
multiple global currencies including the euro, the British pound, the
Japanese yen, and the Australian dollar etc…
Gold Priced In Australian Dollars (Monthly – 20 Year)
Gold in Aussie dollar terms looks like one of the greatest bull markets of the last twenty years.
Gold Priced In Euros (Monthly – 20 Year)
New all-time high for gold priced in euro terms above 1500 euros per ounce!
Gold Priced In British Pounds (Monthly – 20 Year)
A new all-time high for gold in pound sterling terms!
Gold Priced In Japanese Yen (Monthly – 20 Year)
Â¥184,000 per ounce!
Got
the picture? Gold is experiencing a global rally, and gold in US dollar
terms is the only chart that has yet to make a new all-time recently.
However, a new high for gold in US dollar terms may not be that far
away…
Gold Priced In US Dollars (Monthly – 20 Year)
All of these charts share a similar story of
global currencies losing value relative to the only true store of value
that has stood the test of time, gold.
The US dollar has
recently benefited from its perceived safety and the relative strength
of the US economy compared to the eurozone, Japan, UK etc. The US stock
market has been the envy of the world since the March 2009 bottom with a
more than 400% gain for the S&P 500. However, there are mounting
signs that gold could outperform mega-cap US stocks over the coming
years.
In his brilliant “Paradigm Shift”
blog post, Ray Dalio laid out many of the reasons why he is much less
optimistic on future returns from equities and most forms of debt:
“I
think that it is highly likely that sometime in the next few years, 1)
central banks will run out of stimulant to boost the markets and the
economy when the economy is weak, and 2) there will be an enormous
amount of debt and non-debt liabilities (e.g., pension and healthcare)
that will increasingly be coming due and won’t be able to be funded with
assets. Said differently, I think that the paradigm that we are in will
most likely end when a) real interest rate returns are pushed so low
that investors holding the debt won’t want to hold it and will start to
move to something they think is better and b) simultaneously, the large
need for money to fund liabilities will contribute to the “big squeeze.â€
At that point, there won’t be enough money to meet the needs for it, so
there will have to be some combination of large deficits that are monetized, currency depreciations, and large tax increases,
and these circumstances will likely increase the conflicts between the
capitalist haves and the socialist have-nots. Most likely, during this
time, holders of debt will receive very low or negative nominal and real
returns in currencies that are weakening, which will de facto be a
wealth tax.”
Without delving into Dalio’s thesis
and debating future market returns, I don’t think it’s much of a leap to
look at the following chart and quickly surmise that i’d rather be long
than short:
Gold/S&P 500 Ratio Chart (Monthly – 20 Year)
The gold/S&P ratio peaked in 2011 and
proceeded to enter a seven year bear market correction which bottomed in
2018. If gold has indeed resumed its secular bull market (which new
highs in pretty every global currency appears to be confirming) then we
can expect the gold/S&P ratio to also move higher and eventually
move back above 1.0 (one ounce of gold in USD terms worth more than the
S&P 500 Index). Even a .6 ratio value would mean new all-time highs
for gold in USD terms (at Friday’s S&P 500 closing value of 3,337).
There are a lot of things to like in the above chart, but two stand out to me:
The
monthly 14-period Relative Strength is moving above the median line
after multiple tests of the 50 level in the last several years – this is
characteristic of the early stages of a bull market.
The
gold/S&P 500 ratio retested its initial bull market breakout peak
from early 2003 (~.40) and has spent the last 18 months wedging higher –
this ratio could be on the verge of embarking upon a much more
aggressive upward trajectory.
While gold is up
more than 20% in the last year, we haven’t heard much about it from the
mainstream media. Anecdotally, I don’t hear anyone talking about gold
aside from a small clique of gold bull die-hards and my usual sources on
Twitter and CEO.ca – the people who were
all in on cryptocurrencies in January 2018 and cannabis stocks in
February 2019 are no where near gold right now.
Welcome to the gold bull market of the roaring 2020s, it’s just getting started so why don’t you get comfortable and stay a while….
Posted in All Recent Posts, Loncor | Comments Off on The Gold Bull Market Of The Roaring 2020s Has Just Begun SPONSOR: Loncor Resources $LN.ca $ABX.ca $TECK.ca $RSG $NGT.to $GOLD $NEM
Posted by AGORACOM
at 11:01 AM on Tuesday, February 25th, 2020
SPONSOR: ZEN Graphene Solutions: An emerging advanced materials and graphene development company with a focus on new solutions using pure graphene and other two-dimensional materials. Our competitive advantage relies on the unique qualities of our multi-decade supply of precursor materials in the Albany Graphite Deposit. Independent labs in Japan, UK, Israel, USA and Canada confirm this. Click here for more information
Researchers proposed a new design of the supercapacitor, which uses
films of graphene laminate with the same distance between the layers.
Energy density increases drastically — about 10 times compared to conventional supercapacitors.
Scientists from University College London and the Chinese Academy of Sciences have proposed a graphene-based design for supercapacitors, which reportedly increased their density by 10 times.
Supercapacitors charge quickly but also discharge at a high speed.
Existing supercapacitors tend to have a low energy density – about 1/20
of the battery capacity. Batteries
combined with supercapacitors are already in limited use – for example,
in Chinese public transport. But the bus in which such a battery is
installed is forced to charge at almost every stop.
In this work, the researchers proposed a new design of the
supercapacitor, which uses films of graphene laminate with the same
distance between the layers.
The work showed that when the pores in the membranes exactly
correspond to the size of the electrolyte ions, the energy density
increases drastically — about 10 times compared to conventional
supercapacitors.
In addition, the scientists note, the new material has a long service
life, retaining 97.8% of its energy intensity after 5000 cycles of
charging and discharging. The new supercapacitors are also very flexible
– they can be bent up to 180 degrees.
Posted by AGORACOM
at 9:27 AM on Tuesday, February 25th, 2020
SPONSOR: Lomiko Metals is focused on the exploration and development of minerals for the new green economy such as lithium and graphite. Lomiko owns 80% of the high-grade La Loutre graphite Property, Lac Des Iles Graphite Property and the 100% owned Quatre Milles Graphite Property. Lomiko is uniquely poised to supply the growing EV battery market. Click Here For More Information
TESLA REACHES $100 BILLION MARKET CAPITALIZATION WHILE MORGAN STANLEY PREDICTS $1200 LEVEL COMING SOON
Toronto, Ontario, Feb. 25, 2020 (GLOBE NEWSWIRE) — Lomiko Metals Inc. (“Lomikoâ€)
(TSX-V: LMR, OTC: LMRMF, FSE: DH8C) Lomiko Metals Inc. is pleased to
announce that the company will attend the Prospectors & Developers
Association Conference at the Metro Toronto Convention Centre March 1-4,
2020. Lomiko will be at booth #2547 in the Investors Exchange portion
of the Conference. Lomiko is focused on developing graphite materials
supply for the green economy.
Prospects for developing critical minerals mines in Quebec were
buoyed when Canada and the US announced January 9, 2020 they have
finalized the Canada-US Joint Action Plan on Critical Minerals
Collaboration. The Plan is aimed to secure a North American supply
chain for the critical minerals needed for manufacturing
sectors, communication technology, aerospace and defense, and clean
technology.
Canada has significant resources of graphite, lithium, cobalt, aluminum, and rare-earths.
Media has also focused on Tesla in recent interviews with CEO A. Paul
Gill who has consistently spoken about the coming change in consumer
purchasing patterns. In the last decade, range anxiety and concerns
over infrastructure have limited the penetration of electric vehicles in
the North American market and this has cast doubt on the potential of
Tesla. However, it is clear that those fears have been alleviated and
with the onset of new electric vehicles from Ford, GM, BMW, Audi,
Volkswagen, and others.
“Tesla stock price closing in on $ 1000 per share and its valuation
has exceeded $ 100 billion. This is a major indicator that investors
think electric vehicles will become mainstream. Every day, I see at
least one or more. And every time I see one, I think about the battery
it holds which contains up to 70 kgs of graphite.â€, stated A. Paul Gill,
CEO of Lomiko Metals, “That’s why Lomiko looked for projects with good
infrastructure, high grades, and high carbon purity so we could make
strides toward participating in the supply chain of electric vehicles
with materials such as spherical graphite and graphite anodes.â€
Mr. Gill has been interviewed on the Los Angles TV Show Big Biz and
the Geekery Review in Salt Lake City, Utah focusing on Tesla, EV
Batteries and Natural Flake Graphite.
Posted by AGORACOM-JC
at 6:10 AM on Tuesday, February 25th, 2020
Company intends to utilize its database of 165,000 patients to further psilocybin research, develop new products and partner with global leaders in the field
“Empower is uniquely positioned to immediately impact research, develop new products and bring advancements to plant-based therapies, under a framework of rapidly increasing awareness and a movement toward decriminalization of psychedelic treatment options.” said Steven McAuley, Chairman & CEO of Empower
VANCOUVER, BC / February 25, 2020 / EMPOWER CLINICS INC.(CSE:CBDT)(OTC:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented life sciences company is pleased to announce it intends to leverage its existing clinic network, the developing franchise brand, its 165,000 patients and product development capability, to create psilocybin and psychedelics subsidiaries.
The Company has been conducting market research on advancements in
psilocybin and psychedelics in North America and globally, along with
building the business case internally on how to create greater
shareholder value, utilizing Company assets that include clinics,
patients, physicians and technology.
“There is an undeniable mental health crisis in our country and
around the world, that has an ever-increasing, devastating affect on our
society.” said Steven McAuley, Chairman & CEO of Empower. “Empower
is uniquely positioned to immediately impact research, develop new
products and bring advancements to plant-based therapies, under a
framework of rapidly increasing awareness and a movement toward
decriminalization of psychedelic treatment options.”
Studies conducted by nationally and internationally recognized
medical institutions indicate that psilocybin has shown efficacy,
tolerability, and safety in the treatment of a variety of mental health
conditions, including but not limited to addiction, depression, anxiety
disorders, and end-of-life psychological distress.
“Over the past seven years, we have assisted over one hundred
thousand patients obtain access to alternative health care and medicinal
cannabis. The provision of legal access to psilocybin therapies are
perfectly in-line with our philosophy of providing a Scientific Approach
to Alternative Medicine™“, said Dustin Klein, SVP
Business Development and Director, Empower Clinics Inc. “Clinical trials
have shown that psilocybin therapies provide tremendous help with
conditions we see everyday in our clinics. It is our responsibility, to
make sure we are providing the most up-to-date alternative therapies to
our patients and our community.”
The mental health crisis could cost the world $16 trillion by 2030
and according to Future Market Insights; the global behavioral health
(non-pharmacological) market is expected to be valued at US$156 billion
by 2028.
The United States Food and Drug Administration has determined that
preliminary clinical evidence indicates psilocybin may demonstrate
substantial improvement over other available therapies for
treatment-resistant depression; and granted a Breakthrough Therapy
designation for a treatment that uses psilocybin as a therapy for such
depression.
The Company also announces it has issued to Haywood Securities Inc.,
4,000,000 common shares of the Company (the “Work Fee Shares”) under the
financial advisory agreement dated September 25, 2019 (the “Agreement”)
based on Haywood Securities Inc. completing the final written SWOT
analysis. The shares issued are priced at fair market value of the
common shares of the Corporation as at the date of issuance of the Work
Fee Shares.
ABOUT EMPOWER
Empower is a vertically-integrated health & wellness brand with
it’s first hemp-derived CBD extraction facility under development, the
Company produces its proprietary line of cannabidiol (CBD) based
products and distributes products through company owned and franchised
clinics, with wholesale partnerships, online channels and with new
retail opportunities nationwide in the U.S. The company is a leading
multi-state operator of a network of physician-staffed wellness clinics,
focused on helping patients improve and protect their health, through
innovative physician recommended treatment options. The Company has
commenced activity on how to connect its significant data, to the
potential of the efficacy of alternative treatment options related to
hemp-derived cannabidiol (CBD) therapies, psilocybin and other
psychedelic plant-based treatment options.
ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley Chief Executive Officer
CONTACTS:
Investors: Steven McAuley Chairman & CEO [email protected] 604-789-2146
Investors: Dustin Klein SVP, Business Development [email protected] 720-352-1398
For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain “forward-looking statements”
or “forward-looking information” (collectively “forward looking
statements”) within the meaning of applicable Canadian securities laws.
All statements, other than statements of historical fact, are
forward-looking statements and are based on expectations, estimates and
projections as at the date of this news release.Forward-looking statements
can frequently be identified by words such as “plans”, “continues”,
“expects”, “projects”, “intends”, “believes”, “anticipates”,
“estimates”, “may”, “will”, “potential”, “proposed” and other similar
words, or information that certain events or conditions “may” or “will”
occur. Forward-looking statements in this news release include
statements regarding; the Company’s intention to create psilocybin and
psychedelics divisions, that market research on advancements in
psilocybin and psychedelics in North America and globally will create
greater shareholder value, the Company’s intention to open a hemp-based
CBD extraction facility, the expected benefits to the Company and its
shareholders as a result of the proposed acquisitions and partnerships;
the effectiveness of the extraction technology; the expected benefits
for Empower’s patient base and customers; the benefits of CBD based
products; the effect of the approval of the Farm Bill; the growth of the
Company’s patient list and that the Company will be positioned to be a
market-leading service provider for complex patient requirements in 2019
and beyond. Such statements are only projections, are based on
assumptions known to management at this time, and are subject to risks
and uncertainties that may cause actual results, performance or
developments to differ materially from those contained in the
forward-looking statements, including; that the Company may not open a
hemp-based CBD extraction facility; that legislative changes may have an
adverse effect on the Company’s business and product development; that
the Company may not be able to obtain adequate financing to pursue its
business plan; general business, economic, competitive, political and
social uncertainties; failure to obtain any necessary approvals in
connection with the proposed acquisitions and partnerships; and other
factors beyond the Company’s control. No assurance can be given that any
of the events anticipated by the forward-looking statements will occur
or, if they do occur, what benefits the Company will obtain from them.
Readers are cautioned not to place undue reliance on the forward-looking
statements in this release, which are qualified in their entirety by
these cautionary statements. The Company is under no obligation, and
expressly disclaims any intention or obligation, to update or revise any
forward-looking statements in this release, whether as a result of new
information, future events or otherwise, except as expressly required by
applicable laws.
SOURCE: Empower Clinics Inc.
Tags: CSE, Hemp, Marijuana, small cap stocks, stocks, tsx, tsx-v Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca to Create #Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic Network $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca
Posted by AGORACOM-JC
at 6:02 AM on Tuesday, February 25th, 2020
Company signed a Letter of Intent to acquire Venom Extracts
One of Arizona’s premier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products.
Venom Extracts reports having generated CDN$ 16.4 million in revenue and CDN$ 2.48 million in EBIDTA from its product line of Cannabis Concentrates, P.H.O Concentrates and Cartridges.
Hollister Biosciences Inc., the creator of California’s #1 hash-infused pre-roll HashBone, enters into Letter of Intent to acquire Venom Extracts, one of Arizona’s largest producers of award-winning medical cannabis distillate and related products
VANCOUVER, Feb. 25, 2020 – Hollister Biosciences Inc.(CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“) – a vertically integrated cannabis branding company with products in 220 dispensaries throughout California, is pleased to announce that the Company signed a Letter of Intent (“LOI“) on February 20th, 2020 to acquire Venom Extracts ( “Venom“), one of Arizona’s premier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products.
HIGHLY ACCRETIVE $20,000,000 ACQUISITION
For the year ended December 31, 2019, Venom Extracts reports having generated CDN$ 16.4 million in revenue and CDN$ 2.48 million in EBIDTA from its product line of Cannabis Concentrates, P.H.O Concentrates and Cartridges. Hollister
cautions that revenue and EBITDA figures have not yet been audited and
are based on reports prepared by Venom management. Though Hollister believes the figures to be highly reliable, their audit will be part of the due diligence before closing.
The all stock purchase price is anticipated to be CDN$ 20,000,000, with 70% to be paid upfront and 30% to be paid upon milestone achievements. The acquisition is expected to close by March 31, 2020 subject to normal course due diligence.
“Venom has established itself as a leading extraction operation with a prominent brand in the Arizona marketplace”, said Carl Saling,
Founder and CEO of Hollister Biosciences Inc. “We feel this
acquisition will present a great deal of opportunity for synergy between
Hollister and Venom, providing avenues for both companies into the Arizona, California
and additional marketplaces for cannabis products. Venom Extracts has a
highly skilled and experienced management team with a track record for
operational excellence. This transaction is highly accretive and
represents a fundamental part of the future growth of both companies.”
LOI TERMS
The terms of the LOI, which will be formalized by a definitive agreement on closing, are as follows:
The Company will acquire Venom Extracts for CDN$20,000,000 with such payment to be issued in Hollister common stock (the “Payment Shares“)
The stock price will be determined based on the greater of:
The 14-day VWAP (Volume Weighted Average Price) capped at $0.25 subsequent to announcing the transaction and $0.20
Once the share price is established, 70% of the Payment Shares will
be issued upon closing of the transaction, subject to hold periods.
The remaining 30% of the Payment Shares will be issued when and if the following milestones have been met on or prior to December 31st, 2021:
20% (of the total number of Payment Shares) will be issued when revenue of Venom Extracts reaches CDN$ 30,000,000 (calculated in accordance with IFRS from January 1, 2020).
10% (of the total number of Payment Shares) will be issued when revenue of Venom Extracts reaches CDN$ 40,000,000(calculated in accordance with IFRS from January 1, 2020).
“We are very pleased to be entering into this transaction with Hollister”, shared Mason Cave,
CEO of Venom Extracts. “The opportunities for resource and capability
sharing between the two companies are plentiful. This also represents a
more expeditious avenue for us into the large and rapidly growing California marketplace. Hollister
has an excellent management team in place and has established itself as
a sought-after brand house of popular cannabis and hemp products in
California. We feel that our contribution on the extraction side will
help diversify Hollister’s product offering and continue to
build out the brand equity of both companies across multiple state and
eventually global marketplaces”
In association with the arm’s length transaction, Hollister
will not be assuming any long-term debt, a new control position will be
created and there is no change in Management, or the Board of Directors
of Hollister being contemplated at this time.
Finder’s fees will be payable in accordance with the policies of the Canadian Securities Exchange.
About Hollister Biosciences Inc.
Hollister Biosciences Inc. is a vertically integrated cannabis
company with multiple, high-quality products now carried in 220 of Indus
Holdings (CSE: INDS), Hollister’s
exclusive distribution partner’s 600 dispensaries. This level of
penetration is expected to grow as the Company accelerates its seed to
shelf, high margin business and product development model.
Capitalizing on this success, Hollister’s vision is to
become the sought-after premium brand portfolio of innovative, high
quality cannabis across multiple states and hemp products nationwide.
Our wholly owned California subsidiary, Hollister Cannabis Co, is the 1st state and locally licensed Cannabis Company in the City of Hollister, California,
the birthplace of the “American Biker” from which we embrace the outlaw
roots of Hollister to drive our Company fearlessly down the road of
success.
Products from Hollister Cannabis Co. include HashBone, the brand’s
premier artisanal hash-infused pre-roll ranked as California’s #1 hash
infused pre-roll, along with solvent-free bubble hash, pre-packaged
flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD
pet tinctures.
Venom Extracts is one of Arizona’s premier extract
brands and one of the state’s largest producers of award-winning medical
cannabis distillate and related products. With an experienced
management team and unparalleled reputation for quality, Venom Extracts
prides itself as a differentiated extraction company by producing legal
Marijuana products at a price point that allows retailers to generate
higher profits. Focused on proprietary efficiencies, the Company is
able to produce more product per square foot than its competition,
maintaining lower costs and risks than a typical extraction company. The
company’s expansion strategy is centered on entering new markets/states
that are approved for medical cannabis use and/or approved or have a
reasonable expectation to be approved for recreational use in the near
future.
Neither the Canadian Securities Exchange nor its Market Regulator
(as that term is defined in the policies of the Canadian Securities
Exchange) accepts responsibility for the adequacy or accuracy of this
release.
Forward-Looking Information: This news release includes certain
statements that may be deemed “forward-looking statements”. The use of
any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”,
“will”, “would”, “project”, “should”, “believe” and similar expressions
are intended to identify forward-looking statements. Although the
Company believes that the expectations and assumptions on which the
forward-looking statements are based are reasonable, undue reliance
should not be placed on the forward-looking statements because the
Company can give no assurance that they will prove to be correct. Since
forward-looking statements address future events and conditions, by
their very nature they involve inherent risks and uncertainties. These
statements speak only as of the date of this News Release. Actual
results could differ materially from those currently anticipated due to a
number of factors and risks including various risk factors discussed in
the Company’s disclosure documents which can be found under the
Company’s profile onwww.sedar.com
Tags: Cannabis, CSE, Hemp, Marijuana, stocks, tsx, tsx-v Posted in Featured, Hollister Biosciences | Comments Off on Hollister Biosciences $HOLL.ca Signs Letter of Intent to Acquire Venom Extracts With $16.4 Million In Revenue And $2.48 Million EBITDA $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca
